Endologix Inc. (ELGX) gapped open sharply lower Thursday morning and has continued to fall in early trade. The stock is now down 2.35 at $4.38 on above average volume. Endologix has dropped below support and has set a new low for the year.
Endologix announced Wednesday that, after a meeting with the FDA, it will conduct a confirmatory clinical study of its Nellix EVAS System. The company now estimates that PMA approval will occur in 2020.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.